New Millennium Chief Faces Questions and Uncertainties, Acknowledges Takeda Pharmaceutical Co. Ltd. Restructuring May Lead to Job Cuts

Published: Jun 18, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

When you take over one of the Boston area’s largest biopharmaceutical companies after the longtime chief executive has quit abruptly — and as its parent company is shrinking research and development globally — you will be peppered with inquiries. “There’s a lot of questions about what’s happening at Millennium,” Anna Protopapas, the new president of Millennium Pharmaceuticals, acknowledged in an interview Monday. For now, though, when nervous Millennium scientists and confused industry officials approach Protopapas about their concerns and the uncertainty hanging over the company, the 48-year-old Millennium veteran is better able to offer reassurance than clear answers. Millennium’s corporate parent, Japan’s Takeda Pharmaceutical Co., is “working through the process” of restructuring its worldwide research operations, Protopapas said. That probably means some people will be out of work.

Help employers find you! Check out all the jobs and post your resume.

Back to news